Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C27H23N5O4.H2O |
| Molecular Weight | 981.0205 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O=C(NC1=CC=CC2=C1OC(=CC2=O)C3=NN=NN3)C4=CC=C(OCCCCC5=CC=CC=C5)C=C4.O=C(NC6=C7OC(=CC(=O)C7=CC=C6)C8=NN=NN8)C9=CC=C(OCCCCC%10=CC=CC=C%10)C=C9
InChI
InChIKey=MSXTUBJFNBZPGC-UHFFFAOYSA-N
InChI=1S/2C27H23N5O4.H2O/c2*33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18;/h2*1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32);1H2
| Molecular Formula | C27H23N5O4 |
| Molecular Weight | 481.5026 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.e-search.ne.jp/~jpr/PDF/ONO04.PDF
Curator's Comment: description was created based on several sources, including
http://www.e-search.ne.jp/~jpr/PDF/ONO04.PDF
Pranlukast is an antagonist of cysteinyl leukotriene receptor-1 antagonist. It is marketed in Japan by Ono Pharmaceuticals under trademark ONON for the treatment of bronchial asthma and allergic rhinitis as capsules and dry syrup for pediatric use.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1798 |
23.0 nM [IC50] | ||
Target ID: CHEMBL4330 |
3620.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ONON Approved UseONON capsules are indicated for treatment of bronchial asthma |
|||
| Primary | ONON Approved UseONON capsules are indicated for treatment of allergic rhinitis |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | 2013-11 |
|
| Over-expression of the LTC4 synthase gene in mice reproduces human aspirin-induced asthma. | 2011-08 |
|
| Antileukotriene drugs in the treatment of asthma. | 2010-03 |
|
| Pranlukast attenuates ischemia-like injury in endothelial cells via inhibiting reactive oxygen species production and nuclear factor-kappaB activation. | 2009-01 |
|
| Role of regular treatment with inhaled corticosteroid or leukotriene receptor antagonist in mild intermittent asthma. | 2008-04-24 |
|
| Protective effect of pranlukast, a cysteinyl-leukotriene receptor 1 antagonist, on indomethacin-induced small intestinal damage in rats. | 2007-12 |
|
| Cysteinyl leukotriene receptor 1 is involved in N-methyl-D-aspartate-mediated neuronal injury in mice. | 2006-12 |
|
| Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4. | 2006-11 |
|
| Evaluation of theophylline or pranlukast, a cysteinyl leukotriene receptor 1 antagonist, as add-on therapy in uncontrolled asthmatic patients with a medium dose of inhaled corticosteroids. | 2005-11-08 |
|
| Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism. | 2005-02 |
|
| Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. | 2004-05 |
|
| [Clinical effects of long-term administration of pranlukast, a leukotriene receptor antagonist, on adult patients with bronchial asthma]. | 2003-10 |
|
| Clinical effects of long-term administration of pranlukast, a leukotriene receptor antagonist, on adult patients with bronchial asthma. | 2003 |
|
| Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. | 2002-10 |
|
| Long-term observations of the clinical course after step down of corticosteroid inhalation therapy in adult chronic asthmatics: correlation with serum levels of eosinophil cationic protein. | 2002-09 |
|
| Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. | 2002-04-15 |
|
| Evaluation of the combined effect of pranlukast during high-dose steroid inhalation. | 2002 |
|
| Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors. | 2001-11-01 |
|
| Fulminant eosinophilic endomyocarditis in an asthmatic patient treated with pranlukast after corticosteroid withdrawal. | 2001-09 |
|
| Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma. | 2001-08 |
|
| Churg-Strauss syndrome after reduction of inhaled corticosteroid in a patient treated with pranlukast for asthma. | 2001-05 |
|
| Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics. | 2001-02 |
|
| Characterization of the human cysteinyl leukotriene 2 receptor. | 2000-09-29 |
|
| The protective effects of leukotriene modifiers in aspirin-induced asthma. | 2000-09-15 |
|
| A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lung parenchyma. | 2000-06 |
|
| Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity. | 1999-09-20 |
|
| Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. | 1999-09 |
|
| Characterization of the human cysteinyl leukotriene CysLT1 receptor. | 1999-06-24 |
|
| Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast. | 1999-03 |
|
| Leukotriene C4 is a tight-binding inhibitor of microsomal glutathione transferase-1. Effects of leukotriene pathway modifiers. | 1999-01-22 |
|
| Development of 2,2-dimethylchromanol cysteinyl LT1 receptor antagonists. | 1998-12-15 |
|
| Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitro. | 1998-06 |
|
| Pharmacology of leukotriene receptor antagonists | 1998-06 |
|
| Inhibition of 5-lipoxygenase diminishes neurally evoked tachykinergic contraction of guinea pig isolated airway. | 1998-05 |
|
| Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. | 1998-02 |
|
| Effect of pranlukast, a leukotriene receptor antagonist, in patients with severe asthma refractory to corticosteroids. | 1998 |
|
| Therapeutic effect of pranlukast, a selective cysteinyl leukotriene receptor antagonist, on bronchial asthma. | 1997-09 |
|
| Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism. | 1997-05 |
|
| [Cough-variant asthma successfully treated with a peptide leukotriene receptor antagonist]. | 1997-01 |
Sample Use Guides
The usual adult dosage for oral use is 450 mg of pranlukast hydrate (4 capsules) daily in two divided doses after each meal in the morning and evening. The dosage may be adjusted according to the patient's age and symptoms.
Route of Administration:
Oral
The activity of pranlukast was measured using calcium mobilization assay. HEK 293 cells stably expressing CysLT1 receptor and Gα16 protein were loaded with 2 uM Fluo-4 AM in Hanks balanced salt solution buffer. The compound was added to a solution, and after 10 min incubation at room temperature, 25 uL LTD4 was dispensed into the well using a FlexStation II microplate reader, and intracellular calcium change was recorded with an excitation wavelength of 485 nm and an emission wavelength of 525 nm. The IC50 for pranlukast was 23 nM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:13:21 GMT 2025
by
admin
on
Mon Mar 31 19:13:21 GMT 2025
|
| Record UNII |
FR702N558K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29712
Created by
admin on Mon Mar 31 19:13:21 GMT 2025 , Edited by admin on Mon Mar 31 19:13:21 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID9021180
Created by
admin on Mon Mar 31 19:13:21 GMT 2025 , Edited by admin on Mon Mar 31 19:13:21 GMT 2025
|
PRIMARY | |||
|
C96713
Created by
admin on Mon Mar 31 19:13:21 GMT 2025 , Edited by admin on Mon Mar 31 19:13:21 GMT 2025
|
PRIMARY | |||
|
150821-03-7
Created by
admin on Mon Mar 31 19:13:21 GMT 2025 , Edited by admin on Mon Mar 31 19:13:21 GMT 2025
|
PRIMARY | |||
|
FR702N558K
Created by
admin on Mon Mar 31 19:13:21 GMT 2025 , Edited by admin on Mon Mar 31 19:13:21 GMT 2025
|
PRIMARY | |||
|
11979774
Created by
admin on Mon Mar 31 19:13:21 GMT 2025 , Edited by admin on Mon Mar 31 19:13:21 GMT 2025
|
PRIMARY | |||
|
SUB22915
Created by
admin on Mon Mar 31 19:13:21 GMT 2025 , Edited by admin on Mon Mar 31 19:13:21 GMT 2025
|
PRIMARY | |||
|
Pranlukast hydrate
Created by
admin on Mon Mar 31 19:13:21 GMT 2025 , Edited by admin on Mon Mar 31 19:13:21 GMT 2025
|
PRIMARY | |||
|
100000091542
Created by
admin on Mon Mar 31 19:13:21 GMT 2025 , Edited by admin on Mon Mar 31 19:13:21 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |